Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of February 2021, with a filing date of February 24, 2021. The document serves as a report of a foreign private issuer regarding a corporate governance update.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report contains no financial statements or performance data.
Material Changes
The primary material change disclosed is the rescheduling of the Company's Extraordinary Meeting of Shareholders. The meeting was originally scheduled for March 31, 2021, and has been moved to April 6, 2021, at 4:00 p.m. Israel time. The location remains the offices of Gross & Co. in Tel Aviv, Israel.
Guidance, Outlook, and Risks
The filing does not contain management commentary on business outlook, financial guidance, risks, contingencies, or unusual items. It strictly addresses the logistical change to the shareholder meeting date and incorporates the Notice of Extraordinary Meeting of Shareholders as Exhibit 99.1.
Key Facts for Investor Verification
- Verify the new date for the Extraordinary Meeting of Shareholders: April 6, 2021.
- Confirm the meeting time: 4:00 p.m. Israel time.
- Review Exhibit 99.1 for the full Notice of Extraordinary Meeting of Shareholders.
- Note that this filing contains no financial performance data.